LeadershipHBV-experienced, results-driven, and accomplished leadership team

Dr De La Rosa is the Chairman of the Board of Directors and a cofounder of Antios Therapeutics. He was most recently Antios’ Chief Executive Officer and led it from an early-stage idea to a clinical-stage biopharmaceutical company. Prior to Antios, Dr De La Rosa was Chief Scientific Officer of Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (EIDD), focused on the discovery and development of antiviral drugs for the treatment of viral diseases of unmet medical need and global concern. During his nearly 6-year tenure at Emory University, he helped raise over $40 million in funding and was a coinventor on technologies licensed to AbbVie and Antios.

Prior to joining Emory University, Dr De La Rosa was Senior Vice President of Business Development and Scientific Affairs at Pharmasset. From 2002 until its acquisition by Gilead Sciences (NASDAQ: GILD) for $11 billion in 2012, he was responsible for licensing, strategic transactions, and alliance management of collaborations and partnerships with pharmaceutical companies and universities. He provided business and scientific leadership to drug development programs for the treatment of HIV, hepatitis B, and hepatitis C, including sofosbuvir. Prior to Pharmasset, Dr De La Rosa held both scientific and business positions at Visible Genetics, where he was responsible for the development and improvement of genotyping tests for HIV, hepatitis B, and hepatitis C, including the first sequencing-based HIV drug resistance test to receive FDA approval. He also held scientific positions at Innogenetics, Boston Biomedica, and Digene, developing molecular diagnostic tests for infectious diseases. He is an inventor and author on several US patents and publications relating to molecular diagnostic methods, techniques, and therapeutics for infectious diseases and cancer. Dr De La Rosa has served on Scientific Advisory Boards and Board of Directors of biotechnology companies.

Dr De La Rosa earned a Fogarty Fellowship and an Intramural Research Training Award Fellowship from the National Institutes of Health, where he completed post-doctoral training in the Laboratory of Biochemistry and the Laboratory of Pathology of the National Cancer Institute. He holds a Bachelor’s Degree in Microbiology from the University of California, San Diego, and a PhD in Microbiology from Miami University.

Dr Mayers is the Chief Medical Officer and a cofounder of Antios Therapeutics. He was most recently Chief Medical Officer at Cocrystal Pharma (NASDAQ: COCP) developing antiviral drugs against hepatitis B, hepatitis C, and influenza viruses. Notably, in 2007, Dr Mayers was named Executive Vice President and Chief Medical Officer at Idenix Pharmaceuticals where he was responsible for drug safety and clinical development for therapies targeting HIV, hepatitis B, and hepatitis C. After Idenix was acquired by Merck Pharmaceuticals (NYSE: MRK) in 2014, he served for a year as a Principal Investigator at the United States Army Medical Research Institute of Infectious Diseases coordinating efforts to develop drugs against Ebola and MERS coronavirus. Dr Mayers was commissioned into the United States Navy in 1981 and retired after 38 years of service as a Captain, initially serving as a Staff Internist and rising to Department Head, Division of Retrovirology, where he was responsible for directing HIV natural history studies and clinical trials at Army, Navy, and Air Force sites domestically. In 1998, Dr Mayers left Navy active duty to become the Head of the Division of Infectious Diseases at Henry Ford Hospital. He served as Principal Investigator for the clinical trials unit funded by The National Institutes of Health (NIH) and conducted NIH-funded clinical trials of antiviral drugs and the clinical implications and management of HIV drug resistance. In 2001, he moved to Boehringer Ingelheim Pharmaceuticals as the International Head/Vice President of the Therapeutic Area Virology where he was responsible for the therapeutic area strategy and global clinical development and support for antiviral drugs including nevirapine and tipranavir.

Dr Mayers has served as a consultant to the Food and Drug Administration, as a member of numerous Federal and NIH committees, study sections, and advisory groups. He has authored numerous publications and is the editor for the 2-volume textbook, Antimicrobial Drug Resistance, and is a Fellow of the American College of Physicians and the Infectious Disease Society of America.

He received the Jay P. Sanford Award for lifetime professional achievement from the Armed Forces Infectious Disease Society. He holds a Bachelor’s Degree in Electrical Engineering from Pennsylvania State University, and a Doctor of Medicine from the University of Pennsylvania.

Ms Adams has more than 25 years of experience in accounting and financial management. Before joining Antios, she founded Accounting Concepts, Inc., a firm that provided CFO, accounting, and financial services to emerging growth companies in the biopharmaceutical and information technology industries, including Engage Therapeutics, a company that was sold to UCB in 2020. Before that, Ms Adams was a senior financial executive at Silverstorm Technologies, Inc., where she was responsible for financial and human resources functions and participated in an acquisition of the company by QLogic. Prior, she was the Controller of Starcite, Inc., an internet company, where she was responsible for financial reporting, business model development, and internal control systems. Ms Adams began her career at Ernst & Young, LLP, as a Senior Auditor specializing in entrepreneurial services, and later at Goldman Sachs as a Senior Accounting Officer.

Ms Adams earned her Bachelor of Science degree in Accounting at State University of New York, Albany and was a certified public accountant in New York.

Dr Lockwood has 20+ years of experience in the pharmaceutical industry in both process and medicinal chemistry. He began his pharmaceutical career at Abbott Laboratories, where he was part of the process chemistry group responsible for bringing Kaletra to market. He moved from large pharma to be a part of several startup biotech companies in the Atlanta area, including Somatacor Pharmaceuticals, AtheroGenics, Metastatix, and the Emory Institute for Drug Development, where he developed a process for the manufacture of molnupiravir, an antiviral drug licensed to Ridgeback (and later Merck). Molnupiravir is currently in phase 2/3 clinical trials for the treatment of COVID-19. Dr Lockwood is currently Director of Process Research and Manufacturing at Antios Therapeutics and is the coauthor on numerous scientific publications and patents.

Dr Lockwood received his PhD from Purdue University and was a post-doctoral associate at the University of Washington.

Dr Squires started as a Research and Development Project Manager at Antios before her current position as Director of Research and Development. Prior to joining Antios, she served as an Associate Project Manager at Q² Solutions, where she managed over $43 million in phase 1 to 3 clinical trial startup projects and led global project teams through the design phase of study-specific databases with a focus on Alzheimer’s disease. Since joining Antios, Dr Squires has managed the preclinical development program of the company’s lead molecule, ATI-2173, and recently led the acquisition of a novel HBV capsid assembly modulator program.

Dr Squires earned a PhD in Molecular Pharmacology at Emory University and a Bachelor of Arts degree in Textile Engineering at North Carolina State University.